Ajulemic acid (AjA), a synthetic nonpsychoactive cannabinoid, and lipoxin A(4) (LXA(4)), an eicosanoid formed from sequential actions of 5- and 15-lipoxygenases (LOX), facilitate resolution of inflammation. The purpose of this study was to determine whether the ability of AjA to limit the progress of inflammation might relate to an increase in LXA(4), a known anti-inflammatory and proresolving mediator. Addition of AjA (0-30 microM) in vitro to human blood and synovial cells increased production of LXA(4) (ELISA) 2- to 5-fold. Administration of AjA to mice with peritonitis resulted in a 25-75% reduction of cells invading the peritoneum, and a 7-fold increase in LXA(4) identified by mass spectrometry. Blockade of 12/15 LOX, which leads to LXA(4) synthesis via 15-HETE production, reduced (>90%) the ability of AjA to enhance production of LXA(4) in vitro. These results suggest that AjA and other agents that increase endogenous compounds that facilitate resolution of inflammation may be useful for conditions characterized by inflammation and tissue injury.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669421 | PMC |
| http://dx.doi.org/10.1096/fj.08-118323 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study.
JID Innov
January 2025
Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
Article Synopsis
- - Dermatomyositis (DM) is a rare autoimmune disease affecting the skin and is often difficult to treat, with standard medications sometimes ineffective; lenabasum, a selective cannabinoid receptor 2 agonist, shows promise in managing these skin-related symptoms.
- - In a study involving a 3-year open-label extension of a Phase 2 trial with 20 patients resistant to traditional treatments, researchers assessed the long-term effectiveness and recurrence of DM symptoms while on lenabasum.
- - Results indicated significant improvements in skin disease activity and stability, with 58.3% of patients maintaining stable conditions and a notable reduction in flare-ups, suggesting lenabasum as a viable treatment for difficult-to-manage DM cases. *
Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist.
J Pharmacol Exp Ther
October 2024
Department of Psychiatry, Columbia University Irving Medical Center, New York, New York (R.L., S.D.C.); Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University, New York, New York (R.L., G.M., R.S., S.D.C.); and Corbus Pharmaceuticals, Norwood, Massachusetts (A.K., I.H.).
Endocannabinoids, which are present throughout the central nervous system (CNS), can activate cannabinoid receptors 1 and 2 (CB1 and CB2). CB1 and CB2 agonists exhibit broad anti-inflammatory properties, suggesting their potential to treat inflammatory diseases. However, careful evaluation of abuse potential is necessary.
View Article and Find Full Text PDFThe Features of Shared Genes among Transcriptomes Probed in Atopic Dermatitis, Psoriasis, and Inflammatory Acne: S100A9 Selection as the Target Gene.
Protein Pept Lett
September 2024
College of Biological and Environmental Sciences, Zhejiang Wanli University, Ningbo, P.R. China.
Background: Atopic dermatitis (AD), psoriasis (PS), and inflammatory acne (IA) are well-known as inflammatory skin diseases. Studies of the transcriptome with altered expression levels have reported a large number of dysregulated genes and gene clusters, particularly those involved in inflammatory skin diseases.
Objective: To identify genes commonly shared in AD, PS, and IA that are potential therapeutic targets, we have identified consistently dysregulated genes and disease modules that overlap with AD, PS, and IA.
Syntheses of Cannabinoid Metabolites: Ajulemic Acid and HU-210.
Molecules
January 2024
Shanghai Key Laboratory of Crime Scene Evidence, Shanghai Research Institute of Criminal Science and Technology, Shanghai 200072, China.
Cannabinoid metabolites have been reported to be more potent than their parent compounds. Among them, ajulemic acid (AJA) is a side-chain analog of Δ-THC-11-oic acid, which would be a good template structure for the discovery of more potent analogues. Herein, we optimized the key allylic oxidation step to introduce the C-11 hydroxy group with a high yield.
View Article and Find Full Text PDFValidation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and Other Efficacy Outcomes as Measures of Skin Disease in Dermatomyositis in the Lenabasum Phase 3 Trial.
J Invest Dermatol
December 2023
Corporal Micheal J. Crescenz Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address:
In the past decade, there have been six industry-sponsored phase 3 trials in adult patients with dermatomyositis (DM), primarily focusing on improving muscle weakness. However, skin disease is a cardinal manifestation of DM. This study evaluated the sensitivity of Cutaneous Dermatomyositis Disease Area and Severity Index Activity score, Cutaneous Dermatomyositis Activity Investigator Global Assessment, Total Improvement Score, and other outcome measures used in DM clinical trials to detect improvement in DM skin disease activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!